Successful percutaneous coronary intervention for acute coronary syndrome in a patient with haemophilia B

Erkan Köklü, M.D., Nermin Bayar, M.D., İsa Öner Yüksel, M.D., Murat Esin, M.D., Şakir Arslan, M.D.

Department of Cardiology, Antalya Training and Research Hospital, Antalya

Summary– Haemophilia is a congenital coagulation defect brought about by the deficiency or lack of coagulation factor IX. The prevalence of coronary artery disease and acute coronary syndrome (ACS) is lower among haemophiliacs than in the normal population. However, with the administration of factor concentrate, average life expectancy can now extend to as long as 70 years in patients with haemophilia, and this in turn is leading to an increase in the prevalence of cardiac diseases among this population. Data regarding a treatment protocol for ACS and percutaneous coronary intervention (PCI) in patients with congenital coagulation defects is limited. We report a 41-year-old male patient with haemophilia B who presented with a non-ST elevation myocardial infarction, and on whom PCI was performed following monitoring of factor IX levels. The patient had no cardiovascular risk factor except smoking.

Hemophilia B is a congenital coagulation defect caused by the absence of factor IX, and inherited in an X-linked recessive pattern.[1] Eighty-five percent of haemophiliacs are haemophilia A and 15% are haemophilia B, which has a frequency of 1/50,000. Owing to innovations in the treatment of haemophilia, and particularly the use of factor IX concentrate, life expectancy among haemophiliacs is now comparable to that among the normal population.[2,3] On a parallel with this, the incidence of cardiovascular diseases has also grown among haemophilia patients. Acute coronary syndrome (ACS) is rare among haemophiliacs since the hypocoagulable state tends to augment bleeding and serves to protect against thrombotic events in patients with congenital coagulation defects.[4,5] However, when it occurs, it is vital to manage the balance between bleeding and thrombosis in the patient on whom percutaneous coronary intervention (PCI) is performed. Data concerning this clinical entity is restricted.

We present a 41-year-old male patient with haemophilia B presenting with non-ST elevation myocardial infarction (NSTEMI). The patient’s plasma factor IX levels were monitored and PCI successfully performed.

Abbreviations:

- ACS: Acute coronary syndrome
- aPTT: Activated partial thromboplastin time
- ASA: Acetylsalicylic acid
- BMS: Bare metal stent
- CAG: Coronary angiography
- NSTEMI: Non-ST elevation myocardial infarction
- STEMI: ST elevation myocardial infarction
- PCI: Percutaneous coronary intervention

© 2015 Turkish Society of Cardiology

Received: July 18, 2014  Accepted: March 13, 2015

Correspondence: Dr. Erkan Köklü, Yenigün Mahallesi, 1067 Sokak, 6b/13, Muratpaşa, Antalya. Tel: +90 242 - 249 44 00  e-mail: drerkankoklu@gmail.com
A forty-one-year-old male patient with haemophilia B presented to another hospital with squeezing chest pain. NSTEMI was diagnosed and acetylsalicylic acid (ASA) 300 mg and clopidogrel 300 mg were administered. He was transferred to our hospital 8 hours after diagnosis. He was having atypical chest pains lasting 1–2 minutes which were not accompanied by electrocardiographic changes. While his physical examination, electrocardiogram and echocardiogram were normal, troponin I was ascertained to be 2.4 ng/ml (normal value <0.06 ng/ml). His blood pressure and heart rate were 110/70 mmHg and 68/min respectively, and haemogram and biochemical parameters were all within normal ranges. INR was 1.13 and activated partial thromboplastin time (aPTT) was 52 seconds (normal range 25–36 seconds). The patient had been using 1000 units of factor IX three times weekly. He was referred to the haematology department in order to arrange early intervention.

A target of +70% was set for factor IX level at pre-procedure and for 3 days post-procedure. With his level at only 8%, the patient was administered 3500 units of factor IX intravenously (immune factor IX, Eczacibaşı-Baxter) one hour before coronary angiography (CAG). Following the infusion of factor IX, aPTT was 39 seconds. Atorvastatin 20 mg, metoprolol 50 mg and ramipril 5 mg were added to his medication. No typical chest pain necessitating additional medication occurred. CAG was performed using JR4 and JL4 6F catheters via the right femoral artery 18 hours after the patient’s first complaint of chest pain. Heparin was not given pre- or post-procedure. CAG revealed non-significant lesions in the left coronary arteries, and 99% stenosis in the posterolateral branch of the right coronary artery (RCA) (Figure 1a). A 2.5x14 mm bare metal stent (BMS) was implanted (Figure 1b). Following 2 hours of PCI, the sheath was removed and the entry site manually compressed for 15 minutes. Neither bleeding nor haematoma was observed in the right groin. 1000 u, 1000 u and 500 u of factor IX were given daily for 3 days post-procedure as the patient’s levels of factor IX were 54%, 49% and 59% respectively. At the end of one month, clopidogrel was stopped and ASA 100 mg and other medications were continued. During a follow-up of 8 months, the patient remained stable for cardiac outcome.

Atherosclerosis increases with ageing in haemophilia patients. Biere-Rafi et al. stated that the number of deaths owing to arterial thrombosis was 50% lower in patients with haemophilia than in the normal population. Moreover, while intima-media thickness of the carotid and femoral arteries was the same in both populations, the prevalence of atherosclerotic plaque was lower in patients with haemophilia. Death due to coronary artery disease and ACS is reported as diminished in patients with haemophilia compared with the...
Successful PCI for ACS in a patient with haemophilia B

The variance of cardiovascular risk factors for patients with haemophilia is different from the normal population. A large European cross-sectional study revealed that hypertension was more frequent (49% vs. 40%), and obesity and hypercholesterolemia were lower (15% vs. 20%, 44% vs. 68%, respectively) in patients with haemophilia than in the normal population, while the percentages for smoking and diabetes mellitus were similar in both groups. Our patient was young compared to those in the literature, and the only cardiovascular risk factor present was smoking.

Indications and timing of urgent CAG and indications of primary PCI are the same in haemophiliacs and non-haemophiliacs. Patients with haemophilia and ST elevation myocardial infarction (STEMI) should be directed to centres capable of primary PCI as fibrinolytic therapy is contraindicated in patients with haemophilia. The guidelines also emphasize that factor IX levels of more than 80% could result in thrombosis, and recommend that factor IX level be higher than 5–15%, particularly in patients taking dual antiplatelet therapy. In long-term follow-up, the guidelines call for factor IX level to be kept above 5% if the patient is taking dual antiplatelet therapy and above 1% if the patient is taking only ASA in order to avoid bleeding. In our case, the patient’s factor IX level on admission was 8%, which we consider was due to the administration of factor IX concentrate 30 hours before chest pain began. We maintained factor IX level at approximately 70% for 72 hours, which is longer than the guidelines recommend. The dosage was calculated using this formula: Factor IX level needed = (factor IX level targeted – plasma factor IX level) x 2 x plasma volume (40 u/kg x body weight). Our patient’s weight was 73 kg. Plasma factor IX level of 8% and target plasma factor IX level was 70%. Factor IX level needed = (0.70–0.08) x 2 x 40 u/kg x 73 = 3620 u. Thereafter, the patient continued to take 3 doses of 1000 u of factor IX per week, as he had been doing prior to treatment.

There is no exact data on factor IX levels to be obtained in various clinical situations in patients with haemophilia. The European Society of Cardiology (ESC) guidelines on acute coronary syndromes in patients with haemophilia recommend that the level of factor IX be kept around 50% (30%–80%) for 24 hours after PCI in patients with haemophilia. The guidelines also emphasize that factor IX levels of more than 80% could result in thrombosis, and recommend that factor IX level be higher than 5–15%, particularly in patients taking dual antiplatelet therapy. In long-term follow-up, the guidelines call for factor IX level to be kept above 5% if the patient is taking dual antiplatelet therapy and above 1% if the patient is taking only ASA in order to avoid bleeding. In our case, the patient’s factor IX level on admission was 8%, which we consider was due to the administration of factor IX concentrate 30 hours before chest pain began. We maintained factor IX level at approximately 70% for 72 hours, which is longer than the guidelines recommend. The dosage was calculated using this formula: Factor IX level needed = (factor IX level targeted – plasma factor IX level) x 2 x plasma volume (40 u/kg x body weight). Our patient’s weight was 73 kg. Plasma factor IX level of 8% and target plasma factor IX level was 70%. Factor IX level needed = (0.70–0.08) x 2 x 40 u/kg x 73 = 3620 u. Thereafter, the patient continued to take 3 doses of 1000 u of factor IX per week, as he had been doing prior to treatment.

Thrombocyte count and functions are normal in haemophilia patients. Dual antiplatelet therapy is recommended owing to the risk of stent thrombosis after PCI. On the other hand, the use of antiaggregant treatment increases bleeding risk, particularly in the gas-
The addition of proton pump inhibitors to antiaggregant treatment is recommended to reduce this risk. Bare metal rather than drug eluting stents are recommended because the switch from dual antiplatelet therapy to single antiplatelet treatment should be done as soon as possible. Thus, one month is generally adequate for dual antiplatelet therapy and ASA is generally continued after 1 month. Antiaggregant doses are applied as in patients without haemophilia. We considered that administration of an additional 300 mg of clopidogrel to our patient was more convenient. A BMS was also used for our patient and loading doses of ASA and clopidogrel were given. ASA 100 mg and clopidogrel 75 mg were prescribed for one month, following which clopidogrel was abandoned and ASA was recommended indefinitely.

PCI may be quite reliable in patients with haemophilia provided that factor IX levels are monitored closely. Use of a BMS, and dual antiplatelet therapy for one month may reduce bleeding complications.

**Conflict-of-interest issues regarding the authorship or article:** None declared.

**REFERENCES**


**Key words:** Acute coronary syndrome; angioplasty, balloon, coronary; factor IX, coagulation; hemophilia B; percutaneous coronary intervention.

**Anahtar sözcükler:** Akut koroner sendrom; anjiyoplasti, balon, koroner; faktör IX, koagülasyon; hemofili B; perkütan koroner girişim.